Posts by Yin, Jiale

With the global aging population, treatment strategies for breast cancer patients over 70 years old have garnered increasing attention. At the 2024 SABCS conference, a patient-level meta-analysis conducted by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) addressed the impact of immediate versus delayed surgery on outcomes in operable breast cancer patients aged 70+ (Abstract No.: LB1-01). The study highlighted that, for operable breast cancer patients over 70 who did not receive radiotherapy, immediate surgery significantly reduced local recurrence rates and positively influenced long-term survival. This research not only provides robust evidence for treatment decision-making in elderly breast cancer patients but also prompts a reevaluation of therapeutic strategies for this population. Oncology Frontier invited Dr. Baoliang Guo from The Second Affiliated Hospital of Harbin Medical University to provide insightful commentary on this study.

Global breast cancer researchers are tackling cutting-edge questions to inform clinical trial design and guide future treatment decisions. At the 2024 San Antonio Breast Cancer Symposium (SABCS), an internationally renowned panel of experts explored two of the most pressing topics in translational medicine—how to define triple-negative breast cancer (TNBC) and the development of tumor-agnostic therapies.

The 2024 European Society for Medical Oncology Asia Congress (ESMO Asia 2024) was held in Singapore from December 6 to 8. In the session featuring selected oral presentations on thoracic oncology, Professor  Wentao Fang from Shanghai East Hospital, Tongji University presented findings from the AL3810-202 trial (Abstract 625O), which evaluated Lucitanib (Delitinib, AL3810) as a second-line or subsequent therapy for advanced recurrent or metastatic thymic carcinoma. During the conference, Oncology Frontier invited Professor Fang to discuss the study findings and share highlights from the event.

At the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), Dr. Xinping Cao from Sun Yat-sen University Cancer Center presented a comprehensive lecture titled “Advances in Systemic Therapy for Cervical Cancer.” Below is a summary of the key highlights.

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has rapidly advanced in the treatment of lung cancer in recent years. However, challenges remain, such as limited efficacy with monotherapy and increased side effects with combination therapies. Multi-targeted combination therapies represent a potential avenue for advancing immunotherapy. Among them, bispecific antibodies (BsAbs), which simultaneously target two different antigens or epitopes, have emerged as a focus of attention for their ability to enhance the immune system's recognition and destruction of tumor cells.

Modern advancements in oncology have introduced various breakthrough treatment options for lung cancer, which is now one of the most rapidly evolving solid tumors. To help clinicians stay updated on key advancements in this field, Oncology Frontier has partnered with Dr. Hua Zhong and Dr. Baohui Han of the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital to launch the Zhōng & Huì Insights clinical progress series. Through in-depth analyses of high-quality clinical research in lung cancer, the series aims to elevate clinical practice standards. In this 24th installment, the professors discuss the results of the study titled "Efficacy and Safety of Docetaxel Combined with Plinabulin in Second-Line Treatment for Mutation-Negative Advanced NSCLC Patients," published in The Lancet Respiratory Medicine by Dr. Baohui Han as the first author.